PoxSTG - Transgene
Alternative Names: chimeric oncolytic poxvirusLatest Information Update: 30 Aug 2023
At a glance
- Originator Transgene
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Jun 2023 Transgene has patent protection for oncolytic virus technology platform Invir.IO® (Trangene pipeline, June 2023)
- 14 Apr 2023 Preclinical trials in Cancer in France (Parenteral) before April 2023
- 14 Apr 2023 Pharmacodynamics data from preclinical studies in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)